Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toluene SCHEMBL28207041 | 0.98 | NAPRT (0.73) | NAPRTSMN1; SMN2TSHRKDM4ELMNA | |
| 3-Methylpyridine SCHEMBL27722549 | 0.90 | NAPRT (0.65) | NAPRTSMN1; SMN2TSHRKDM4ELMNA | |
| Pyridine SCHEMBL25354696 | 0.89 | NAPRT (0.69) | NAPRTSMN1; SMN2TSHRKDM4ELMNA | |
| SCHEMBL65447 | 0.87 | NAPRT (1.00) | NAPRTSMN1; SMN2TSHRKDM4EALDH1A1 | |
| SCHEMBL29727824 | 0.87 | NAPRT (1.00) | NAPRTSMN1; SMN2TSHRKDM4EALDH1A1 | |
| Toluene SCHEMBL29249545 | 0.86 | SMN1; SMN2 (0.59) | NAPRTSMN1; SMN2TSHRKDM4ELMNA | |
| Pyridine SCHEMBL28513140 | 0.85 | NAPRT (0.88) | NAPRTSMN1; SMN2TSHRKDM4EALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL8023386 | 0.85 | NAPRT (0.96) | NAPRTSMN1; SMN2TSHRKDM4EALDH1A1 | |
| SCHEMBL1649252 | 0.85 | NAPRT (0.96) | NAPRTSMN1; SMN2TSHRKDM4EALDH1A1 | |
| SCHEMBL5082269 | 0.85 | NAPRT (0.96) | NAPRTSMN1; SMN2TSHRKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| EP-3700911-A1 | NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Les Laboratoires Servier SAS (FR) | 2020-09-02 | — | — | EP | disclosed |
| US-5792840-A | SUBSTITUTED GLUCOPYRANOSYL PHOSPHATES | SANKYO COMPANY, LIMITED (JP) | 1998-08-11 | — | — | US | disclosed |
| EP-0143557-A2 | Griseolic acid derivatives, and their use | SANKYO COMPANY LIMITED (JP) | 1985-06-05 | — | — | EP | disclosed |
| US-4203976-A | ANTHELMINTICS, INSECTICIDES, PARASITICIDES, MITICIDES | MERCK & CO., INC. (US) | 1980-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | CFD, CFH, TFPI | NAPRT 2136/4885SMN1; SMN2 4033/4885TSHR 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.